[
    [
        {
            "time": "2018-01-02",
            "original_text": "AbbVie (ABBV) Stock Moves -1.54%: What You Should Know",
            "features": {
                "keywords": [
                    "AbbVie",
                    "stock moves",
                    "-1.54%"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "AbbVie (ABBV) Stock Moves -1.54%: What You Should Know",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Neurocrine Inks Deal with Private Biotech to Make CNS Drugs",
            "features": {
                "keywords": [
                    "Neurocrine",
                    "deal",
                    "CNS drugs"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Neurocrine Inks Deal with Private Biotech to Make CNS Drugs",
                "Correlation": 2,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 1,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "CLASS ACTION UPDATE for ABBV, ALNY and ADNT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",
            "features": {
                "keywords": [
                    "class action",
                    "ABBV",
                    "ALNY",
                    "ADNT"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "CLASS ACTION UPDATE for ABBV, ALNY and ADNT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",
                "Correlation": 8,
                "Sentiment": 2,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",
            "features": {
                "keywords": [
                    "shareholder alert",
                    "class action lawsuit",
                    "AbbVie"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",
                "Correlation": 10,
                "Sentiment": 1,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In AbbVie Inc. (NYSE: ABBV) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit",
            "features": {
                "keywords": [
                    "shareholder alert",
                    "Brower Piven",
                    "AbbVie"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In AbbVie Inc. (NYSE: ABBV) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit",
                "Correlation": 10,
                "Sentiment": 1,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "J&J's Stelara Succeeds in Phase III Ulcerative Colitis Study",
            "features": {
                "keywords": [
                    "J&J",
                    "Stelara",
                    "Phase III",
                    "ulcerative colitis"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "J&J's Stelara Succeeds in Phase III Ulcerative Colitis Study",
                "Correlation": 4,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 2,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Ex-Dividend Reminder: AbbVie, ConnectOne Bancorp and Pennymac Mortgage Investment Trust",
            "features": {
                "keywords": [
                    "ex-dividend",
                    "AbbVie",
                    "ConnectOne Bancorp",
                    "Pennymac Mortgage"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "financial services"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Ex-Dividend Reminder: AbbVie, ConnectOne Bancorp and Pennymac Mortgage Investment Trust",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 6,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 5,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "How Novartis’s Sandoz Business Has Been Performing Recently",
            "features": {
                "keywords": [
                    "Novartis",
                    "Sandoz",
                    "performance"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "How Novartis’s Sandoz Business Has Been Performing Recently",
                "Correlation": 1,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 2,
                "Duration": 4,
                "Entity_Density": 1,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        }
    ]
]